1-9 of 9
Jian Li
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies

Michael C. Heinrich, Xinhua Zhang, Robin L. Jones, Suzanne George, César Serrano, Yanhong Deng, Sebastian Bauer, Shirong Cai, Xin Wu, Yongjian Zhou, Kaixiong Tao, Zhichao Zheng, Jun Zhang, Yuehong Cui, Hui Cao, Meining Wang, Jin Hu, Jason Yang, Jian Li, Lin Shen
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (4): 719–728.
https://doi.org/10.1158/1078-0432.CCR-23-1861
Published: 16 February 2024
View article titled, Clinical Benefit of Avapritinib in <em>KIT-</em>Mutant Gastrointestinal Stromal Tumors: A <em>Post Hoc</em> Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies
Open the PDF for Clinical Benefit of Avapritinib in <em>KIT-</em>Mutant Gastrointestinal Stromal Tumors: A <em>Post Hoc</em> Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies in another window
Includes: Supplementary data
Journal Articles

Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II Study

Jian Li, Shirong Cai, Yongjian Zhou, Jun Zhang, Ye Zhou, Hui Cao, Xin Wu, Yanhong Deng, Zhao Huang, Juan Dong, Lin Shen
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (16): 3425–3432.
https://doi.org/10.1158/1078-0432.CCR-22-0196
Published: 15 August 2022
View article titled, Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II Study
Open the PDF for Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II Study in another window
Includes: Supplementary data
Journal Articles

Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor–Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002)

Xin Hua, Xi-Wen Bi, Jian-Li Zhao, Yan-Xia Shi, Ying Lin, Zhi-Yong Wu, Yuan-Qi Zhang, Le-Hong Zhang, An-Qing Zhang, Heng Huang, Xin-Mei Liu, Fei Xu, Ying Guo, Wen Xia, Ruo-Xi Hong, Kui-Kui Jiang, Cong Xue, Xin An, Yong-Yi Zhong, Shu-Sen Wang, Jia-Jia Huang, Zhong-Yu Yuan
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (4): 637–645.
https://doi.org/10.1158/1078-0432.CCR-21-3435
Published: 15 February 2022
View article titled, Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor–Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002)
Open the PDF for Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor–Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002) in another window
Includes: Supplementary data
Journal Articles

Abstract A61: FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy

Carlos J. Díaz Osterman, Duygu Ozmadenci, Elizabeth G. Kleinschmidt, Kristin N. Taylor, Allison M. Barrie, Shulin Jiang, Lisa M. Bean, Florian J. Sulzmaier, Jian Li, Xiao Lei Chen, Guo Fu, Marjaana Ojalill, Pekka Rappu, Jyrki Heino, Adam A. Mark, Guorong Xu, Kathleen M. Fisch, David T. Weaver, Jonathan A. Pachter, Balázs Győrffy, Michael T. McHale, Denise C. Connolly, Alfredo Molinolo, Dwayne G. Stupack, David D. Schlaepfer
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13_Supplement): A61.
https://doi.org/10.1158/1557-3265.OVCA19-A61
Published: 01 July 2020
View article titled, Abstract A61: FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy
Journal Articles

Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial

Ming Lu, Panpan Zhang, Yanqiao Zhang, Zhongwu Li, Jifang Gong, Jie Li, Jian Li, Yan Li, Xiaotian Zhang, Zhihao Lu, Xicheng Wang, Jun Zhou, Zhi Peng, Weifeng Wang, Hui Feng, Hai Wu, Sheng Yao, Lin Shen
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (10): 2337–2345.
https://doi.org/10.1158/1078-0432.CCR-19-4000
Published: 15 May 2020
View article titled, Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial
Open the PDF for Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial in another window
Journal Articles

Comparing Patient-Derived Xenograft and Computational Response Prediction for Targeted Therapy in Patients of Early-Stage Large Cell Lung Cancer

Jian Li, Changkun Ye, Ulrich R. Mansmann
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (9): 2167–2176.
https://doi.org/10.1158/1078-0432.CCR-15-2401
Published: 01 May 2016
View article titled, Comparing Patient-Derived Xenograft and Computational Response Prediction for Targeted Therapy in Patients of Early-Stage Large Cell Lung Cancer
Open the PDF for Comparing Patient-Derived Xenograft and Computational Response Prediction for Targeted Therapy in Patients of Early-Stage Large Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

HER2-Associated Radioresistance of Breast Cancer Stem Cells Isolated from HER2-Negative Breast Cancer Cells

Nadire Duru, Ming Fan, Demet Candas, Cheikh Menaa, Hsin-Chen Liu, Danupon Nantajit, Yunfei Wen, Kai Xiao, Angela Eldridge, Brett A. Chromy, Shiyong Li, Douglas R. Spitz, Kit S. Lam, Max S. Wicha, Jian Jian Li
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (24): 6634–6647.
https://doi.org/10.1158/1078-0432.CCR-12-1436
Published: 16 December 2012
View article titled, HER2-Associated Radioresistance of Breast Cancer Stem Cells Isolated from HER2-Negative Breast Cancer Cells
Open the PDF for HER2-Associated Radioresistance of Breast Cancer Stem Cells Isolated from HER2-Negative Breast Cancer Cells in another window
Includes: Supplementary data
Journal Articles

Overexpression of HMGA2 Promotes Metastasis and Impacts Survival of Colorectal Cancers

Xiaochen Wang, Xiyong Liu, Angela Ying-Jian Li, Lirong Chen, Lily Lai, Her Helen Lin, Shuya Hu, Lifang Yao, Jiaping Peng, Sofia Loera, Lijun Xue, Bingsen Zhou, Lun Zhou, Shu Zheng, Peiguo Chu, Suzhan Zhang, David Kong Ann, Yun Yen
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (8): 2570–2580.
https://doi.org/10.1158/1078-0432.CCR-10-2542
Published: 14 April 2011
View article titled, Overexpression of HMGA2 Promotes Metastasis and Impacts Survival of Colorectal Cancers
Open the PDF for Overexpression of HMGA2 Promotes Metastasis and Impacts Survival of Colorectal Cancers in another window
Includes: Supplementary data
Journal Articles

Proapoptotic Function of Integrin β3 in Human Hepatocellular Carcinoma Cells

Yanhua Wu, Jie Zuo, Guoqing Ji, Hexige Saiyin, Xing Liu, Feiyu Yin, Ning Cao, Yunfei Wen, Jian Jian Li, Long Yu
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (1): 60–69.
https://doi.org/10.1158/1078-0432.CCR-08-1028
Published: 31 December 2008
View article titled, Proapoptotic Function of Integrin β<sub>3</sub> in Human Hepatocellular Carcinoma Cells
Open the PDF for Proapoptotic Function of Integrin β<sub>3</sub> in Human Hepatocellular Carcinoma Cells in another window
Includes: Supplementary data